AF
OTLK icon

Amalgamated Financial’s Outlook Therapeutics OTLK Stock Holding History

Amalgamated Financial’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$26K Buy
+725
New +$22.6K ﹤0.01% 2664

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Amalgamated Financial's OTLK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Outlook Therapeutics (OTLK) in Q1 2022: 725 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #2664 among its holdings.

73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

  • Amalgamated Financial held 725 shares of Outlook Therapeutics worth $26K as of Q1 2022.
  • Outlook Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Outlook Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2664 holding.
  • 73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.